3.48 USD
+0.17 (+5.14%)
3.47 USD
-0.01 (-0.29%)
We assign a fundamental rating of 2 out of 10 to AQST. AQST was compared to 191 industry peers in the Pharmaceuticals industry. AQST has a bad profitability rating. Also its financial health evaluation is rather negative. AQST is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- AQST had negative earnings in the past year.
- In the past year AQST has reported a negative cash flow from operations.
- In the past 5 years AQST always reported negative net income.
- In the past 5 years AQST always reported negative operating cash flow.
1.2 Ratios
- AQST has a Return On Assets (-42.14%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -42.14% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-50.85%
ROA(5y)-71.01%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of AQST (60.28%) is better than 69.63% of its industry peers.
- In the last couple of years the Gross Margin of AQST has grown nicely.
- AQST does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y2.38%
2. Health
2.1 Basic Checks
- AQST does not have a ROIC to compare to the WACC, probably because it is not profitable.
- AQST has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, AQST has more shares outstanding
- The debt/assets ratio for AQST has been reduced compared to a year ago.
2.2 Solvency
- AQST has an Altman-Z score of -2.05. This is a bad value and indicates that AQST is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -2.05, AQST is in line with its industry, outperforming 41.36% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.05 |
ROIC/WACCN/A
WACC10.03%
2.3 Liquidity
- A Current Ratio of 5.93 indicates that AQST has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 5.93, AQST is in the better half of the industry, outperforming 68.59% of the companies in the same industry.
- AQST has a Quick Ratio of 5.62. This indicates that AQST is financially healthy and has no problem in meeting its short term obligations.
- AQST's Quick ratio of 5.62 is fine compared to the rest of the industry. AQST outperforms 66.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.93 | ||
| Quick Ratio | 5.62 |
3. Growth
3.1 Past
- The earnings per share for AQST have decreased strongly by -61.36% in the last year.
- AQST shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -26.32%.
- The Revenue has been growing slightly by 1.82% on average over the past years.
EPS 1Y (TTM)-61.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.69%
Revenue 1Y (TTM)-26.32%
Revenue growth 3Y4.23%
Revenue growth 5Y1.82%
Sales Q2Q%-5.43%
3.2 Future
- Based on estimates for the next years, AQST will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.25% on average per year.
- AQST is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.25% yearly.
EPS Next Y-26.76%
EPS Next 2Y-3.46%
EPS Next 3Y18.56%
EPS Next 5Y19.25%
Revenue Next Year-23.71%
Revenue Next 2Y4.46%
Revenue Next 3Y17.39%
Revenue Next 5Y31.25%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for AQST. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AQST. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- AQST's earnings are expected to grow with 18.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.46%
EPS Next 3Y18.56%
5. Dividend
5.1 Amount
- AQST does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
3.48
+0.17 (+5.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-03 2026-03-03/amc
Inst Owners53.88%
Inst Owner Change0.37%
Ins Owners4.5%
Ins Owner Change-0.93%
Market Cap424.56M
Revenue(TTM)43.40M
Net Income(TTM)-68.92M
Analysts84
Price Target9.18 (163.79%)
Short Float %21.49%
Short Ratio6.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.44%
Min EPS beat(2)-3.59%
Max EPS beat(2)18.46%
EPS beat(4)1
Avg EPS beat(4)-15.2%
Min EPS beat(4)-38.41%
Max EPS beat(4)18.46%
EPS beat(8)2
Avg EPS beat(8)-15.3%
EPS beat(12)6
Avg EPS beat(12)0.72%
EPS beat(16)10
Avg EPS beat(16)5.11%
Revenue beat(2)0
Avg Revenue beat(2)-8.18%
Min Revenue beat(2)-13.36%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-16.45%
Min Revenue beat(4)-30.1%
Max Revenue beat(4)-2.99%
Revenue beat(8)2
Avg Revenue beat(8)-1.61%
Revenue beat(12)5
Avg Revenue beat(12)1.04%
Revenue beat(16)9
Avg Revenue beat(16)4.52%
PT rev (1m)-12.62%
PT rev (3m)2.56%
EPS NQ rev (1m)3.83%
EPS NQ rev (3m)8.62%
EPS NY rev (1m)-0.28%
EPS NY rev (3m)-0.11%
Revenue NQ rev (1m)-0.48%
Revenue NQ rev (3m)-0.4%
Revenue NY rev (1m)-0.13%
Revenue NY rev (3m)-0.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 9.78 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.71
EYN/A
EPS(NY)-0.56
Fwd EYN/A
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS0.36
BVpS-0.03
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -42.14% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.28% | ||
| FCFM | N/A |
ROA(3y)-50.85%
ROA(5y)-71.01%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y2.38%
F-Score1
Asset Turnover0.27
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 87.5% | ||
| Cap/Sales | 1.15% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.93 | ||
| Quick Ratio | 5.62 | ||
| Altman-Z | -2.05 |
F-Score1
WACC10.03%
ROIC/WACCN/A
Cap/Depr(3y)67.19%
Cap/Depr(5y)49.48%
Cap/Sales(3y)2.51%
Cap/Sales(5y)2.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-61.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.69%
EPS Next Y-26.76%
EPS Next 2Y-3.46%
EPS Next 3Y18.56%
EPS Next 5Y19.25%
Revenue 1Y (TTM)-26.32%
Revenue growth 3Y4.23%
Revenue growth 5Y1.82%
Sales Q2Q%-5.43%
Revenue Next Year-23.71%
Revenue Next 2Y4.46%
Revenue Next 3Y17.39%
Revenue Next 5Y31.25%
EBIT growth 1Y-166.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-77.14%
EBIT Next 3Y12.1%
EBIT Next 5Y29.93%
FCF growth 1Y-956.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-827%
OCF growth 3YN/A
OCF growth 5YN/A
AQUESTIVE THERAPEUTICS INC / AQST FAQ
What is the fundamental rating for AQST stock?
ChartMill assigns a fundamental rating of 2 / 10 to AQST.
What is the valuation status for AQST stock?
ChartMill assigns a valuation rating of 0 / 10 to AQUESTIVE THERAPEUTICS INC (AQST). This can be considered as Overvalued.
How profitable is AQUESTIVE THERAPEUTICS INC (AQST) stock?
AQUESTIVE THERAPEUTICS INC (AQST) has a profitability rating of 1 / 10.
How financially healthy is AQUESTIVE THERAPEUTICS INC?
The financial health rating of AQUESTIVE THERAPEUTICS INC (AQST) is 3 / 10.